Kymbek

Edoxaban, the active ingredient in Kymbek, is a Direct Factor Xa Inhibitor presented as an oral formulation for oral use. It is used to prevent stroke and systemic embolism in non‑valvular atrial fibrillation and to treat or prevent deep vein thrombosis and pulmonary embolism. GNH USA supplies Kymbek as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Edoxaban is indicated for several anticoagulation indications related to thromboembolic disease.

- Non‑valvular atrial fibrillation: reduces risk of stroke and systemic embolism. - Deep vein thrombosis (DVT): treats acute DVT and prevents clot extension. - Pulmonary embolism (PE): treats acute PE and helps prevent recurrence. - Recurrent DVT and PE: provides secondary prevention of venous thromboembolism.

Common Side Effects: - Bruising or minor bleeding at sites of injury. - Nosebleeds (epistaxis). - Gastrointestinal discomfort such as nausea or dyspepsia. - Headache or dizziness. - Mild anemia.

Serious or Rare Side Effects: - Major bleeding, including gastrointestinal hemorrhage. - Intracranial hemorrhage. - Spinal or epidural hematoma. - Severe allergic reactions (anaphylaxis, rash). - Hepatic injury or elevated liver enzymes. - Thrombocytopenia.

When using Kymbek, consider the following precautions: - Renal impairment: assess kidney function and adjust therapy as needed. - Hepatic disease: use with caution in patients with liver dysfunction. - Concomitant anticoagulants: avoid combined use due to heightened bleeding risk. - Surgery or invasive procedures: discontinue before high‑bleed risk interventions. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at room temperature: keep in original container, protect from moisture and light.

Edoxaban may interact with several drug classes.

Major Interactions (Avoid): - Strong P‑gp inhibitors (e.g., ketoconazole, itraconazole): increase edoxaban exposure and bleeding risk. - Combined use with other anticoagulants (warfarin, heparin, dabigatran): risk of severe bleeding. - Antiplatelet agents (high‑dose aspirin, clopidogrel) in patients at high bleed risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may raise plasma levels. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase bleeding tendency. - Diuretics: monitor renal function and electrolytes.